1. HBW Insight

‘Assuming’ OTC Narcan Approval, Emergent Notes Opportunity But Forecasts Full-Year Revenue Dip

 
• By Malcolm Spicer

Sales of Narcan nasal spray were down 14% for the full year to $373.7m and 24% in Q4 to $91.1m, Emergent reported. It includes $290m to $310m estimate for 2023 Narcan sales in guidance for all products and services adding up to $1.1bn to $1.2bn. revenues. “We are assuming that FDA grants approval for OTC treatment of Narcan and … launching this product into the OTC market in the summer," says CEO Robert Kramer.

• Source: Shutterstock

Emergent BioSolutions, Inc. isn’t estimating the amount of potential OTC sales of its naloxone nasal spray in its 2023 results, but made its full-year guidance assuming nonprescription approval, expecting total sales for its naloxone products to be down from $373.7m.

Emergent released its 2022 fourth-quarter and full-year results on 27 February, 12 days after Food and Drug Administration advisory committees voted unanimously to recommend the agency approve the firm’s supplemental new drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation